Targeting these TREM2+ macrophages via genetic ablation of the gene or specific antibodies against the protein reduces tumor growth in animal models; however, it further attenuates tumor growth when combined with immune checkpoint inhibitors (ICI) by promoting the expression of immunostimulatory molecules (Fig. 1). This evidence concerns the gene TREM2 and neoplasm.